Department of Urology, College of Medicine, Chung-Ang University, Seoul 140-757, Korea.
Asian J Androl. 2010 Sep;12(5):766-74. doi: 10.1038/aja.2010.29. Epub 2010 Aug 2.
The aim of this study was to determine the impact that age and comorbidity status have on both overall and bladder cancer-specific survival of bladder cancer patients. We obtained medical information pertaining to a population of 528 patients with newly diagnosed bladder cancer from Chung-Ang University Hospital cancer registry. The Adult Comorbidity Evaluation-27 (ACE-27) test, which has been previously validated in adult cancer patients, was used to assess comorbidity. We evaluated differences in the demographic and clinical characteristics of included patients, as well as differences in the treatments they received after categorizing them by age. The median age at the time of bladder cancer diagnosis of the entire cohort was 63 years, and the median follow-up time was 97 months. Of the 528 patients who were included in our study, 303 had at least one comorbid condition and 249 died during the follow-up period. When patients were stratified by age, we found that older patients had a higher proportion of severe comorbidities (P < 0.01) than younger patients, and that a lower proportion of them underwent radical cystectomy for invasive bladder cancer (IBC) (P < 0.01). By multivariate analysis, we found that older age was predictive of lower overall survival (OS) and bladder cancer-specific survival (BCSS) rates among patients with superficial bladder cancer (SBC) and of lower OS rates among patients with IBC. We also found that moderate-severe comorbidity status and treatment through a bladder-conserving approach were predictive of lower OS and cancer-specific survival rates among patients with IBC. The disparity between overall deaths and bladder cancer deaths was shown in SBC and increased along with age and higher comorbidity. Age and comorbidity were found to be independent predictive factors of OS and BCSS among bladder cancer patients, and explained the disparity that we observed between overall bladder cancer-specific mortality rates.
本研究旨在确定年龄和合并症状态对膀胱癌患者的总体和膀胱癌特异性生存的影响。我们从忠南大学医院癌症登记处获得了 528 名新诊断膀胱癌患者的医疗信息。先前在成年癌症患者中验证过的成人合并症评估-27(ACE-27)测试用于评估合并症。我们评估了纳入患者的人口统计学和临床特征的差异,以及根据年龄对他们进行分类后接受治疗的差异。整个队列的膀胱癌诊断时的中位年龄为 63 岁,中位随访时间为 97 个月。在我们的研究中,528 名患者中有 303 名至少有一个合并症,249 名在随访期间死亡。当患者按年龄分层时,我们发现年龄较大的患者比年龄较小的患者有更高比例的严重合并症(P < 0.01),并且接受根治性膀胱切除术治疗浸润性膀胱癌(IBC)的比例较低(P < 0.01)。通过多变量分析,我们发现年龄较大是预测浅表膀胱癌(SBC)患者总体生存率(OS)和膀胱癌特异性生存率(BCSS)较低的因素,也是 IBC 患者 OS 率较低的因素。我们还发现中重度合并症状态和通过保留膀胱的方法治疗是预测 IBC 患者 OS 和癌症特异性生存率较低的因素。SBC 中总死亡人数和膀胱癌死亡人数之间的差异随着年龄和合并症程度的增加而增加。年龄和合并症是膀胱癌患者 OS 和 BCSS 的独立预测因素,解释了我们观察到的总体膀胱癌特异性死亡率之间的差异。